Numbers of new drug launches in the UK and degree of innovativeness by BNF chapter heading, 2001–2012
| Degree of innovativeness | ||||||||
|---|---|---|---|---|---|---|---|---|
| Slightly (n, % category) | Moderately (n, % category) | Highly (n, % category) | Total (n, % total) | |||||
| Year of new drug launch | ||||||||
| 2001–2004 | 54 | 58.7 | 18 | 19.6 | 20 | 21.7 | 92 | 31.7 |
| 2005–2008 | 50 | 54.9 | 15 | 16.5 | 26 | 28.6 | 91 | 31.4 |
| 2009–2012 | 58 | 54.2 | 20 | 18.7 | 29 | 27.1 | 107 | 36.9 |
| BNF chapter heading | ||||||||
| Anaesthesia | 1 | 33.3 | 1 | 33.3 | 1 | 33.3 | 3 | 1.0 |
| Cardiovascular system | 20 | 58.8 | 6 | 17.6 | 8 | 23.5 | 34 | 11.7 |
| Central nervous system | 18 | 56.3 | 9 | 28.1 | 5 | 15.6 | 32 | 11.0 |
| Ear, nose and oropharynx | 2 | 100.0 | 0 | 0.0 | 0 | 0.0 | 2 | 0.7 |
| Endocrine system | 22 | 66.7 | 7 | 21.2 | 4 | 12.1 | 33 | 11.4 |
| Eye | 9 | 90.0* | 0 | 0.0 | 1 | 10.0 | 10 | 3.4 |
| Gastrointestinal system | 1 | 33.3 | 1 | 33.3 | 1 | 33.3 | 3 | 1.0 |
| Immunological products and vaccines | 6 | 100.0* | 0 | 0.0 | 0 | 0.0 | 6 | 2.1 |
| Infections | 23 | 60.5 | 7 | 18.4 | 8 | 21.1 | 38 | 13.1 |
| Malignant disease and immunosuppression | 19 | 33.3 | 13 | 22.8 | 25 | 43.9† | 57 | 19.7 |
| Musculoskeletal and joint diseases | 9 | 56.3 | 3 | 18.8 | 4 | 25.0 | 16 | 5.5 |
| Nutrition and blood | 14 | 53.8 | 2 | 7.7 | 10 | 38.5 | 26 | 9.0 |
| Obstetrics, gynaecology and urinary-tract disorders | 8 | 80.0 | 1 | 10.0 | 1 | 10.0 | 10 | 3.4 |
| Respiratory system | 8 | 61.5 | 2 | 15.4 | 3 | 23.1 | 13 | 4.5 |
| Skin | 2 | 28.6 | 1 | 14.3 | 4 | 57.1† | 7 | 2.4 |
| Total | 162 | 55.9 | 53 | 18.3 | 75 | 25.9 | 290 | 100 |
*Proportion of slightly innovative drugs greater than total proportion of slightly innovative drugs, p<0.05 (one-tailed χ2 test).
†Proportion of highly innovative drugs greater than total proportion of highly innovative drugs, p<0.05 (one-tailed χ2 test).
BNF, British National Formulary.